Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0TK2N
|
|||
Drug Name |
PMID25522065-Compound-45
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
TAKEDA PHARMACEUTICAL COMPANY LIMITED MASADA, Shinichi
|
|||
Structure |
Download2D MOL |
|||
Formula |
C26H33N3O3
|
|||
Canonical SMILES |
CC1=C(C=CC2=C1C=C(N2C)CNCC(C)(C)O)NC(=O)C3=CC=C(C=C3)OCC4CC4
|
|||
InChI |
1S/C26H33N3O3/c1-17-22-13-20(14-27-16-26(2,3)31)29(4)24(22)12-11-23(17)28-25(30)19-7-9-21(10-8-19)32-15-18-5-6-18/h7-13,18,27,31H,5-6,14-16H2,1-4H3,(H,28,30)
|
|||
InChIKey |
LYUFDXWEPKVSLW-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Melanin-concentrating hormone receptor 1 (MCHR1) | Target Info | Antagonist | [1] |
Target's Patent Info | Melanin-concentrating hormone receptor 1 (MCHR1) | Target's Patent Info | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Reactome | Peptide ligand-binding receptors | |||
G alpha (q) signalling events | ||||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.